Real-world check on new CMV drugs in transplant patients

NCT ID NCT04690933

Completed Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 400 stem cell transplant recipients to see how well anti-CMV medications work in everyday hospital care. Researchers tracked infections, drug resistance, and side effects. The goal was to gather real-life data to improve treatment guidelines for these high-risk patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIVIRAL DRUG RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIVIRAL DRUG RESISTANCE ANTIVIRALS CYTOMEGALOVIRUS INFECTIONS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Contacts and locations

Show contact details

Locations

APHP

Paris, France
CHU

Amiens, France
CHU

Angers, France
CHU

Besançon, France
CHU

Bordeaux, France
CHU

Caen, France
CHU

Clermont-Ferrand, France
CHU

Grenoble, France
CHU

Montpellier, France
CHU

Nancy, France
CHU

Poitiers, France
CHU

Rouen, France
CHU

Saint-Etienne, France
CHU

Strasbourg, France
CHU de LIMOGES

Limoges, Limoges, 87045, France
HCL

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.